Phospho-DRP1 (Ser616) Antibody - #DF2972

Figure 7. siRNA Mzb1 blocks the puerarin increase of ATP content and inhibits Drp-1 phosphorylation in H2O2-treated AC16 cardiomyocytes. (A) Puerarin dose-dependently increased ATP content in H2O2-treated cardiomyocytes (n = 6); (B) siRNA Mzb1 attenuated puerarin’s increase of ATP content in H2O2-treated cardiomyocytes (n = 3); (C) puerarin inhibited Drp1 phosphorylation in H2O2-treated cardiomyocytes (n = 3); (D) siRNA Mzb1 effectively reduced puerarin upregulation of p-Drp1 protein expression in H2O2-treated cardiomyocytes (n = 4). *p < 0.05.

FIGURE 7 Activated AMPK regulated the translocation of Drp1 to mitochondria (A). Evaluation of ATP levels in SHG4 and U87 cells over different time courses of TMZ treatment showed that intracellular levels of ATP decreased within a short period of time after TMZ treatment; there were two troughs in the curve showing ATP concentration over a 24 h period. (B) Evaluation of the expression of phosphorylated AMPKα in tumour cells over different time courses of TMZ treatment revealed that both cell lines were upregulated within 24 h; furthermore, two peaks of phosphorylated AMPKα expression were observed during this time period. (C) In SHG44 cells, the localization of Drp1 and PINK1 in the mitochondria decreased during TMZ treatment. Drp1 and P53 increased in the nucleus, while levels of DRp1 increased in the nucleus. When treated with TMZ+CC, levels of Drp1 and PINK1 increased in the mitochondria while the levels of P53 decreased in the nucleus. Compared with the TMZ group, the levels of Drp1 in the cytoplasm decreased, levels of Drp1 and PINK1 in the mitochondria decreased, and the levels of P53 in the nucleus increased. Under the TMZ+AICAR treatment, levels of Drp1 in the cytoplasm increased significantly.